GlassScriptPhysician profile
Adam Prewitt
NPI 1417589706
$993.92
in general payments reported to CMS, 2019-2025
23 companies · $84.22 in 2025
The $84.22 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $217 · 2023: $89.81 · 2024: $291 · 2025: $84.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $216.00 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $83.88 | 2024-2025 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $81.59 | 2022 | |
| Lilly USA, LLC | $66.10 | 2021-2024 | Mounjaro |
| Abbvie INC. | $64.99 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $59.35 | 2024 | |
| Scilex Pharmaceuticals INC. | $56.41 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $35.86 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.77 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.65 | 2022 | |
| Relievant Medsystems, INC. | $29.33 | 2022 | |
| Glaxosmithkline, LLC. | $28.96 | 2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $27.79 | 2021 | |
| Neurocrine Biosciences, INC. | $26.86 | 2023 | Ingrezza |
| Fidia Pharma USA INC. | $21.66 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.26 | 2024 | |
| Exact Sciences Corporation | $17.00 | 2025 | The Cologuard Plus Collection Kit |
| Grt US Holding, INC. | $16.58 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.25 | 2021 | |
| Novo Nordisk INC | $15.65 | 2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $14.35 | 2024 | |
| Redhill Biopharma INC. | $14.11 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Prewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.